<div id="readability-page-1"><p>Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) insider Dennis Cho sold 324 shares of the firm's stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $34.56, for a total transaction of $11,197.44. Following the completion of the sale, the insider directly owned 144,680 shares in the company, valued at $5,000,140.80. This represents a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.</p><div><p><span></span><span>Get <strong>Twist Bioscience</strong> alerts:</span></p></div><p>Dennis Cho also recently made the following trade(s): </p><ul><li>On Monday, November 3rd, Dennis Cho sold 1,019 shares of Twist Bioscience stock. The stock was sold at an average price of $32.08, for a total value of $32,689.52. </li><li>On Thursday, October 30th, Dennis Cho sold 6,515 shares of Twist Bioscience stock. The shares were sold at an average price of $31.44, for a total value of $204,831.60. </li><li>On Monday, October 6th, Dennis Cho sold 3,876 shares of Twist Bioscience stock. The shares were sold at an average price of $32.19, for a total value of $124,768.44. </li></ul><h2>Twist Bioscience Trading Down 3.5%</h2><p>NASDAQ:TWST traded down $1.22 on Tuesday, hitting $33.84. 804,463 shares of the stock were exchanged, compared to its average volume of 1,350,107. The stock has a fifty day moving average of $31.02 and a 200-day moving average of $31.19. The stock has a market cap of $2.07 billion, a PE ratio of -25.83 and a beta of 2.24. The company has a current ratio of 3.64, a quick ratio of 3.33 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $55.33. </p><p>Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its earnings results on Friday, November 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.05). The firm had revenue of $99.01 million for the quarter, compared to analysts' expectations of $97.40 million. Twist Bioscience had a negative return on equity of 27.40% and a negative net margin of 20.63%. As a group, equities analysts expect that  Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year. </p><h2>Hedge Funds Weigh In On Twist Bioscience</h2><p>A number of institutional investors have recently added to or reduced their stakes in TWST. Quarry LP acquired a new stake in shares of  Twist Bioscience during the third quarter valued at about $28,000.  Smartleaf Asset Management LLC lifted its stake in shares of  Twist Bioscience by 70.6% in the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company's stock worth $29,000 after acquiring an additional 442 shares in the last quarter.  National Bank of Canada FI acquired a new position in shares of  Twist Bioscience in the third quarter worth about $46,000.  Mirae Asset Global Investments Co. Ltd. boosted its holdings in  Twist Bioscience by 15.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company's stock valued at $85,000 after purchasing an additional 302 shares during the last quarter.  Finally, Geneos Wealth Management Inc. acquired a new stake in  Twist Bioscience during the 2nd quarter valued at approximately $97,000. </p><h2>Analyst Ratings Changes</h2><p>A number of brokerages have recently commented on TWST. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Twist Bioscience in a research note on Monday. Stephens assumed coverage on Twist Bioscience in a report on Monday, November 3rd. They issued an &#34;overweight&#34; rating and a $41.00 price target for the company. Barclays raised their price objective on Twist Bioscience from $37.00 to $39.00 and gave the company an &#34;overweight&#34; rating in a research report on Monday, December 15th. Finally, Evercore ISI reduced their price objective on Twist Bioscience from $46.00 to $42.00 and set an &#34;outperform&#34; rating on the stock in a research note on Tuesday, October 7th. Eight research analysts have rated the stock with a Buy rating and two have issued  a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $44.88.</p><p><b>View Our Latest Research Report on Twist Bioscience</b></p><h2>About Twist Bioscience</h2> (Get Free Report)<p>Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.  </p><p>At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Twist Bioscience</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li><li>Forget AI, This Will Be the Next Big Tech Breakthrough</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFdTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFdTVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Twist Bioscience Right Now?</h2><p>Before you consider Twist Bioscience, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list.</p><p>While Twist Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

TWST

<p>Twist Bioscience (NASDAQ:TWST) insider Dennis Cho sold 324 shares for $11,197.44 on December 22nd. Following the sale, Cho owns 144,680 shares, a 0.22% decrease in his position. The transaction was disclosed in an SEC filing. The stock traded down 3.5% to $33.84. Twist Bioscience reported a Q4 loss of $0.45 per share, missing estimates. Analysts have mixed ratings on the stock, with an average target price of $44.88.</p>

Twist Bioscience (NASDAQ:TWST) Insider Sells $11,197.44 in Stock